The research team led by Dr. Moon-Hyeong Seo from the Natural Product Drug Development Center at the Korea Institute of ...

Korean scientists have developed a revolutionary eye drop treatment for dry age-related macular degeneration (AMD), ...

Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

The research team from the Natural Product Drug Development Center at the Korea Institute of Science and Technology has developed a new therapeutic agent for dry Age-related macular ...

Although intravitreal faricimab helped to decrease central subfield thickness (CST) in patients with eyes previously treated ...

The Korea Institute of Science and Technology (KIST) announced on the 18th that it held a signing ceremony for technology ...

After its eye disease antibody flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is ...

Amgen alleged that the 276 patent—which was added to the Patent Register in relation to a Supplementary New Drug Submission ...

for the treatment of wet age-related macular degeneration (wet AMD). In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational and is being evaluated in an ongoing non-inferiority ...

Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular ...

Roche announced that the European Medicines Agency has approved Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular ...